No Data
Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
Express News | Vir Biotechnology Inc : Morgan Stanley Raises to Overweight From Equal-Weight
Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20
Morgan Stanley Upgrades Vir Biotechnology(VIR.US) to Buy Rating, Raises Target Price to $20
Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $26
H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $110